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Background. Environmental factors and genetic mutations have been increasingly recognized as risk factors for chronic pancreatitis
(CP). The PRSS1 p.R122H mutation was the first discovered to affect hereditary CP, with 80% penetrance. We performed here a
systematic review and meta-analysis to evaluate the associations of PRSS1 p.R122H mutation with CP of diverse etiology.
Methods. The PubMed, EMBASE, and MEDLINE database were reviewed. The pooled odds ratio (OR) with 95% confidence
intervals was used to evaluate the association of p.R122H mutation with CP. Initial analysis was conducted with all etiologies of
CP, followed by a subgroup analysis for hereditary and nonhereditary CP, including alcoholic or idiopathic CP. Results. A total
of eight case-control studies (1733 cases and 2415 controls) were identified and included. Overall, PRSS1 p.R122H mutation was
significantly associated with an increased risk of CP (OR= 4.78[1.13–20.20]). Further analysis showed p.R122H mutation
strongly associated with the increased risk of hereditary CP (OR= 65.52[9.09–472.48]) but not with nonhereditary CP, both
alcoholic and idiopathic CP. Conclusions. Our study showing the differential role of p.R122H mutation in various etiologies of
CP indicates that this complex disorder is likely influenced by multiple genetic factors as well as environmental factors.
1. Introduction
Chronic pancreatitis (CP) is a wide range of progressive
fibroinflammatory disease of the exocrine pancreas that
eventually leads to irreversible impairment of exocrine and
endocrine functions of the gland [1, 2]. The incidence of
CP ranges from 4 to 14 per 100,000 worldwide with a higher
incidence reported in recent years [3]. Our understanding of
the pathogenesis and pathophysiology of CP, including the
development of pancreatic fibrosis, etiologic risk factors,
natural history, and genetic and epigenetic changes
associated, has significantly advanced over time [1, 2, 4, 5].
CP has traditionally been classified as alcohol, hereditary,
obstructive, hyperlipidemia, or idiopathic on the basis of eti-
ology [6]. The most common disease phenotype is described
as chronic calcifying pancreatitis, which is characterized by
clinically apparent acute pancreatitis (AP) at the early stage,
progressive development of intraductal stones, pancreatic
ductal distortion, strictures, and pancreatic atrophy and
extensive destruction of the pancreatic parenchyma leading
to steatorrhea and diabetes [3]. Alcohol and smoking are
identified as independent risk factors for CP. Both are
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associated with disease progression, and their risks are likely
multiplicative [2]. Several genetic mutations, including
human cationic trypsinogen (PRSS) 1, PRSS2, serine protease
inhibitor Kazal type 1 gene (SPINK1), chymotrypsinogen C
gene (CTRC), transmembrane conductance regulator gene
(CFTR), and calcium-sensing receptor (CASR), have been
noted as risk factors [2, 6]. The role of these gene mutations
in CP is becoming increasingly recognized, although the pro-
portion of CP with known genetic mutations is rather small.
PRSS1mutation was first discovered to be associated with
the phenotype of hereditary pancreatitis (HP) twenty years
ago [7]. Carriers with this mutation tend to develop recurrent
AP with an early onset of the disease (prior to the second
decade of life) and the development of chronic pancreatitis
and also have a significantly increased risk for development
of pancreatic adenocarcinoma [8, 9]. R122H mutation of
the PRSS1 gene, detected in more than 50% of the patients
with HP, was the most common mutation in patients with
HP [10]. A single G to A transition mutation in the cationic
trypsinogen gene in exon 3 resulted in an arginine (CGC) to
histidine (CAC) substitution at amino acid residue 117 of
trypsinogen (p.R122H) and this amino acid change elimi-
nates a trypsin cleavage site on the surface of trypsinogen
and is predicted to prevent trypsinogen autoinactivation
[7, 11]. Mice expressing mouse PRSS1 mutant p.R122H
transgene exhibited early onset of acinar cell injury and
inflammation that progressed with age to a chronic stage
and associated with fibrosis and acinar cell differentiation
[11]. Expression of human PRSS1 mutants (p.R122H or
p.N29I) in murine pancreatic acinar cells also promoted
pancreatic injury [12]. Interestingly, endogenously activated
trypsinogen (PACE-trypsinogen) in acinar cells caused spon-
taneous development of AP, but did not exhibit the features
of CP, including fibrosis [13]. Genetic deletion of trypsinogen
7, a mouse cationic trypsinogen, caused a 50% reduction in
pancreatic damage in caerulein-induced AP [14], but exhib-
ited the same degree of CP induced by repetitive challenges
of caerulein compared to wild-type mice [15].
In this study, we performed a systematic review andmeta-
analysis to investigate the association between p.R122H
mutation in PRSS1 gene and the risk of CP. We used PRSS1
p.R122H as an example of genetic risk factor in order to
understand more about the association of single genetic fac-
tor in CP patients. We found that PRSS1 p.R122H mutation
was significantly associated with an increased risk of hered-
itary CP. Further analysis suggested p.R122H mutation was
weakly but still significantly associated with an increased risk
of nonhereditary CP, including alcoholic or idiopathic CP
with a slightly greater risk in idiopathic CP.
2. Methods
2.1. Search Strategy. A search of the literature was conducted
by two authors (C.H and L.W) independently using PubMed,
EMBASE, and MEDLINE electronic databases. The key-
words PRSS1 or p.R122H were combined with pancreatitis.
The filter “human” was applied. The search was conducted
using database entries from January 1996 to July 2016.
The language was limited to English. The duplicates were
removed manually. We also reviewed reference list of cita-
tions in the identified publications for additional citations.
2.2. Eligibility Criteria. The published observational studies
found by our search that reported the association of chronic
pancreatitis with p.R122H mutation were included in this
review. Studies that enrolled pediatric patients were excluded
(n = 36). All basic and animal experimental studies were
also excluded (n = 26). Review articles (n = 67) and case
reports (n = 39) were excluded. Studies that investigated
autoimmune pancreatitis (n = 1) or recurrent acute pancrea-
titis (n = 3) were also excluded.
2.3. Data Extraction. Data were extracted by two authors
(C. H and L. W) independently for each individual study.
The following data were extracted: year, study design,
racial background, genotyping method, criteria used for
diagnosis of CP, number of patients diagnosed as CP, total
number of patients, etiology of CP (alcohol, idiopathic,
hereditary, and other), history of alcohol consumption, and
history of smoking if applicable.
2.4. Quality Assessment. The quality of included case-control
studies was systematically assessed using the Newcastle
Ottawa Scale (NOS). A maximum of 9 points were given to
each study within the categories of the selection, comparabil-
ity, and exposure, as scored by two independent observers.
Studies were considered to be “good” quality if they scored
>5 points, whereas studies were considered to be “poor”
quality if they received ≤5 points.
2.5. Definitions. The American Pancreatic Association (APA)
guidelines [2] were used to define disease categories. Heredi-
tary CP was defined as present in an individual with CP and
with one or two affected first-degree relatives or two or more
second-degree relatives affected [16–19]. Nonhereditary CP
included idiopathic CP, alcoholic CP, and other etiologies.
Idiopathic CP was exclusively diagnosed in the absence of
known etiological factors such as alcohol, gallstone, infection,
trauma, medications, age over 65, and a positive family
history [6].
Alcohol was considered the cause of CP in those who
consumed more than 60 or 80 g per day for at least 2 years.
Smokers were defined as those who smoked 10 or more
cigarettes per day for at least 2 years.
2.6. Data Analysis. For each study, the association between
PRSS1 p.R122H mutation and the risk of CP was initially
evaluated. A preliminary meta-analysis combining all studies
included regardless of etiology was conducted. Further strat-
ified analysis was used to assess the risk of hereditary and
nonhereditary CP with PRSS1 p.R122H mutation, including
subanalysis of alcoholic and idiopathic CP. Forest plots were
created showing the pooled odds ratio (OR) with the corre-
sponding 95% confidence intervals (CIs). Data were pooled
using the random effects model to provide a more conserva-
tive estimate. Statistical heterogeneity between studies was
determined with Cochran Q test and the I2 value [20]. High
statistical heterogeneity was defined as >70%, medium het-
erogeneity was defined as 50%–70%, and low heterogeneity
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was defined as 0%–50% [20]. A p value of ≤0.05 was con-
sidered as statistical significance. Sensitivity analysis was
used to test the robustness of associations by omitting
each individual study in turn from all available studies
when appropriate. Publication bias was assessed by visual
inspection of funnel plot [21]. The analysis was performed
by Stata software, version SE/13.0 (Stata Corp LP, College
Station, Texas, USA).
3. Results
3.1. Study Selection.A total of 567 studies were retrieved from
PubMed, EMBASE, and MEDLINE. After removal of dupli-
cates, 258 studies were screened by the title and abstracts.
In the preliminary screening, we excluded 185 studies
because of the following reasons: pediatric patients (n = 36),
animal and experimental studies (n = 28), case reports
(n = 39), cross-sectional studies (n = 1), review (n = 67), edito-
rial (n = 2), and others (n = 12). After removing, seventy-three
articles potentially met the inclusion criteria for eligibility,
and 63 were excluded for the reasons as follows: not
relevant (n = 46), no genotyping for PRSS1 (n = 7), no
genotyping for p.R122H (n = 6), recurrent AP (n = 3),
and autoimmune pancreatitis (n = 1). Overall, ten studies
[16–19, 22–27] were identified and scored for assessing the
quality. Two studies were excluded from meta-analysis due
to quality score≤ 5. Finally, eight studies fulfilled completely
the criteria for inclusion in this current meta-analysis. The
flow diagram showing the study selection process is pre-
sented in Figure 1. Methodological quality assessment of
the included studies is shown in Supplementary Table 1
available online at https://doi.org/10.1155/2017/9505460.
3.2. Study Characteristics. A total of eight case-control-
designed studies including CP patients were selected.
Table 1 shows information published for these studies:
ethnicity, genotyping methods, and etiologies of CP. Six
studies were conducted in Europe and the other two in Asia.
First, we analyzed the eight studies that included a total of
1733 cases and 2415 controls. Then, we analyzed the cases
based on whether subjects had HP or not (non-HP). Finally,
four studies including HP patients (255 cases and 2214
controls) and all eight studies including non-HP patients
(1478 cases and 2415 controls) were enrolled. Further analy-
sis of non-HP patients was carried out using six of the studies
with ACP patients (308 cases and 575 controls) and seven of
the studies with ICP patients (1170 cases and 2315 controls).
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Sc
re
en
in
g
In
clu
de
d
El
ig
ib
ili
ty
Id
en
ti
ca
tio
n Additional records identied
through other sources (n = 0)
Records aer duplicates removed
(n = 258)
Records screened
(n = 258)
Records excluded
(n = 185)
Full-text articles assessed
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qualitative synthesis (n = 10)
Studies included in
quantitative synthesis
(meta-analysis) (n = 8)
Figure 1: Flow chart of study selection [37].
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3.3. Chronic Pancreatitis with All Etiologies Combined. Initial
meta-analysis of individual studies and the combined results
of the eight studies with all etiologies of CP are shown in
Figure 2. The total number of patients from these studies
was 1733 CP cases with 2415 healthy controls. The weighted
OR revealed an association between p.R122H mutation
and that the risk of CP is 4.78 (1.13–20.20). There was
low heterogeneity detected between the studies (p = 0 171
and I2 = 32 2%).
3.4. Hereditary Chronic Pancreatitis versus Nonhereditary
Chronic Pancreatitis. Four of the studies assessed patients
with hereditary CP (255 cases and 2214 controls,
Figure 3(a)). The p.R122H mutation was detected in 39 of
255 cases and none in 2214 controls. There was low hetero-
geneity detected between the studies (p = 0 235 and I2 =
29 5%). The pooled OR revealed an association between
p.R122H mutation and the risk of hereditary CP of 65.52
(9.09–472.48). Eight studies evaluated patients with nonhe-
reditary CP (1478 cases and 2415 controls, Figure 3(b)).
The p.R122H mutation was present in 8 of 1478 cases and
none in 2415 controls. There was low heterogeneity detected
between the studies (p = 0 241 and I2 = 23 6%). The pooled
OR revealed an association between p.R122H mutation,
and an increased risk of nonhereditary CP is 2.79 (95%CI,
0.68–11.55). These data indicate that p.R122H mutation is
strongly associated with hereditary CP and has a weak
association with nonhereditary CP.
3.5. Subgroup Analysis of Alcoholic and Idiopathic CP. Six
studies assessed patients with alcoholic CP (308 cases and
575 controls, Figure 4). The p.R122H mutation was detected
in 8 of 308 cases and none in 575 controls. There was no
heterogeneity detected between the studies (p = 0 662 and
I2 = 0 0%). The pooled OR of 3.39 (0.79–14.54) revealed a
trend that p.R122H mutation may be associated with an
increased risk of alcoholic CP. Since there is only one
study with a small size suggesting an association between
p.R122H mutation and alcoholic CP and 95%CI crossed
1, we think the p.R122H mutation may not be associated
with alcoholic CP, although further study is required to
confirm these findings.
Seven studies assessed patients with idiopathic CP (1170
cases and 2315 controls, Figure 5). The p.R122H mutation
was detected in 9 of 1170 cases and none in 2315 controls.
There was low heterogeneity detected between the studies
(p = 0 330 and I2 = 13 1%). The pooled OR is 4.43 (1.03–
19.05), which revealed a significant weak association between
p.R122H mutation and an increased risk of idiopathic CP.
Consistent with the analysis in nonhereditary CP, there was
a weak but still significant association between p.R122H
mutation and an increased risk of CP.
Table 1: Characteristics of case-control studies included.
Author, year Journal Genotyping method Author country Study population
Non-HP
HP
ACP ICP
Sisman et al., 2015 [27] Turk J Gastroenterol RFLP-PCR Turkey Turkey + +
Madro et al., 2015 [26] Gastroenterol Res Pract RT-PCR Poland N/A +
Rosendahl et al., 2013 [16] Gut PCR Germany German + +
Gasiorowska et al., 2011 [25] Dig Dis Sci RFLP-PCR Poland Polish + +
Mora et al., 2009 [17] Pancreatology RFLP-PCR Spain Spanish + + +
Chandak 2004 [18] Gut — India Indian + + +
Teich et al., 2002 [19] Am J Gastroenterol PCR Germany N/A + +
O’Reilly et al., 2001 [22] Digestion PCR UK Ethnically matched + +
N/A: not available.
Study name
R122H/total Statistics for each study
Cases Controls Odds 
ratio
Lower 
limit
Upper 
limit
Relative
weight (%)
Sisman et al., 2015 0/79 0/35 0.45 0.01 22.96 9.98
Madro et al., 2015 0/79 0/100 1.26 0.02 64.42 10.01
Rosendahl et al., 2013 25/660 0/1758 141.12 8.58 2321.58 15.81
Gasiorowska et al., 2011 9/47 0/46 22.95 1.29 407.07 15.31
Mora et al., 2009 0/97 0/84 0.87 0.02 44.16 10.01
Chandak et al., 2004 0/198 0/290 1.46 0.03 74.07 10.03
Teich et al., 2002 21/523 0/82 7.06 0.42 117.68 15.72
O’Reilly et al., 2001 1/50 0/20 1.24 0.05 31.78 13.14
4.78 1.13 21.20 100.00
0.1 0.5 1
Figure 2: Forest plots showing the association between chronic pancreatitis with all etiologies combined and R122H mutation incidence.
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The sensitivity analysis was performed by sequential
omission of each single study in turn. The results indicated
that removal of any individual studies one at a time did not
change the direction of the pooled effect size (Supplementary
Figure 1), indicating that our results are relatively stable
and credible.
4. Discussion
Overall, we found that the PRSS1 p.R122Hmutation is signif-
icantly associated with an increased risk of CP. Our finding is
consistent with the meta-analysis conducted by Liu and
Zhang [28] which suggested a significant association between
total pancreatitis and the PRSS1 gene. But this study neither
specified the sites of the gene mutations nor compared the
different pancreatitis etiologies. In our current study, we
specifically asked whether there is an association between
PRSS1 p. R122H and chronic pancreatitis with subgroup
analysis applied to the known etiologies. Further analysis
showed that p.R122H mutation is strongly associated with
hereditary CP. Since the first report in 1996 indicating that
PRSS1 p.R122H mutation was associated with the phenotype
of HP in a North American family [7], strong associations
between the p.R122H mutation in the PRSS1 gene and HP
Study name
R122H/total Statistics for each study
Cases Controls Odds
ratio
Lower
limit
Upper
limit
Relative
weight (%)
Rosendahl et al., 2013 18/107 0/1758 726.98 43.46 12160.88 31.08
Mora et al., 2009 0/3 0/84 24.14 0.42 1404.13 18.47
Chandak et al., 2004 0/37 0/290 7.75 0.15 396.23 19.41
Teich et al., 2002 21/108 0/82 40.54 2.42 680.18 31.04
65.52 9.09 472.48 100.00
p = 0.235, I2 = 29.5%
0.1 0.5 1
(a)
Cases Controls Odds
ratio
Lower
limit
Upper
limit
Relative
weight (%)
0.1 0.5 1
Study name
R122H/total Statistics for each study
Sisman et al., 2015 0/79 0/35 0.45 0.01 22.96 10.44
Madro et al., 2015 0/79 0/100 1.26 0.02 64.42 10.47
Rosendahl et al., 2013 7/553 0/1758 48.27 2.75 846.50 16.81
Gasiorowska et al., 2011 9/47 0/46 22.95 1.29 407.07 16.72
Mora et al., 2009 0/94 0/84 0.89 0.02 45.56 10.47
Chandak et al., 2004 0/161 0/290 1.80 0.04 91.09 10.50
Teich et al., 2002 0/415 0/82 0.20 0.00 10.08 10.49
O’Reilly et al., 2001 1/50 0/20 1.24 0.05 31.78 14.10
2.79 0.68 11.55 100.00
p = 0.241, I2 = 23.6%
(b)
Figure 3: Hereditary CP/R122H mutation versus nonhereditary CP/R122H mutation for case-control studies.
Study name
R122H/total Statistics for each study
Cases Controls Odds
ratio 
Lower
limit 
Upper
limit 
Relative
weight (%)
Sisman et al., 2015 0/41 0/35 0.86 0.02 44.23 13.61
Madro et al., 2015 0/79 0/100 1.26 0.02 64.42 13.71
Gasiorowska et al., 2011 7/33 0/46 26.32 1.45 479.43 25.16
Mora et al., 2009 0/78 0/84 1.08 0.02 54.91 13.71
Chandak et al., 2004 0/41 0/290 7.00 0.14 357.59 13.70
O’Reilly et al., 2001 1/36 0/20 1.73 0.07 44.52 20.11
3.39 0.79 14.54 100.00
p = 0.662, I2 = 0.0% 0.1 0.5 1
Figure 4: Alcoholic CP/R122H mutation for case-control studies.
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have been reported in a number of studies from many parts
of the world including Europe and Asia [29–31]. Subgroup
analysis for the known etiologies, including alcoholic and
idiopathic CP, showed that p.R122H mutation is weakly
correlated with an increased risk of nonhereditary CP. In
recent years, smoking has been recognized as an indepen-
dent risk factor affecting the course and progression of CP
[32, 33]. We were unable to investigate the association of
smoking with the risk of CP as there is lack of reported data
extracted from the studies we included in our analysis.
Various PRSS1 gene mutations in exon 2 and exon 3 have
been reported to be pathogenic and associated with the
phenotype of CP. p.R122H and p.N29I mutations are the
most common mutations [34]. Recently, the genome-wide
association study (GWAS) in alcoholic CP discovered that
the common genetic variants in the PRSS1-PRSS2 locus
account for an increased risk for alcoholic and sporadic CP,
but rare PRSS1 gene variants, including three known diseases
that were also screened and identified, were not associated
with the observed phenotype [35]. This finding was repli-
cated and refined in a large European cohort by an indepen-
dent group [36]. Both studies suggested the importance of
continuing to identify disease-associated genetic variants.
In summary, our findings indicate that the PRSS1
p.R122H mutation is significantly associated with an
increased risk of CP overall. The differential role of PRSS1
p.R122H mutation was observed in both hereditary and
nonhereditary CP. These data suggest that multiple genetic
and environmental factors determine the initiation and
progression of CP.
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